title: Update on optimal use of lisdexamfetamine in the treatment of ADHD.
abstract: Lisdexamfetamine (LDX) has been a recent addition to the treatment armamentarium for Attention Deficit Hyperactivity Disorder (ADHD). It is unique among stimulants as it is a prodrug, and has been found to be safe and well-tolerated medication in children older than 6 years, adolescents and adults. It has a smooth onset of action, exerts its action up to 13 hours and may have less rebound symptoms. LDX has proven to be effective in the treatment of ADHD in placebo controlled trials, and improved performance in simulated academic and work environments have been noticed. Both stimulant-naïve and stimulant-exposed patients with ADHD appear to benefit from LDX. It has also shown some promise in improving emotional expression and executive function of patients with ADHD. Adverse effects such as decrease in sleep, loss of appetite and others have been reported with LDX use, just as with other stimulant formulations. Since most such studies exclude subjects with preexisting cardiac morbidity, prescribing precautions should be taken with LDX in such subjects, as with any other stimulant. Study subjects on LDX have been reported to have low scores on drug likability scales, even with intravenous use; as a result, LDX may have somewhat less potential for abuse and diversion. There is a need for future studies comparing other long acting stimulants with LDX in ADHD; in fact clinical trials comparing LDX with OROS (osmotic controlled-release oral delivery system) methylphenidate are currently underway. Furthermore, the utility of this medication in other psychiatric disorders and beyond ADHD is being investigated.
authors.affiliation: Department of Psychiatry and Neurobehavioral Sciences, Division of Child and Family Psychiatry, University of Virginia Health System, Charlottesville, VA, USA.
authors.forename: Vishal
authors.initials: V
authors.lastname: Madaan
authors.forename: Venkata
authors.initials: V
authors.lastname: Kolli
authors.forename: Durga P
authors.initials: DP
authors.lastname: Bestha
authors.forename: Manan J
authors.initials: MJ
authors.lastname: Shah
keywords: ADHD; functional impairment; lisdexamfetamine; pharmacotherapy
references.citation: Clin Ther. 2007 Mar;29(3):450-63
references.pmid: 17577466
references.citation: Neuropsychiatr Dis Treat. 2010 Jun 24;6:317-27
references.pmid: 20628632
references.citation: Drug Metab Dispos. 2007 Jan;35(1):180-4
references.pmid: 17035599
references.citation: Pediatrics. 2005 Jun;115(6):e749-57
references.pmid: 15930203
references.citation: CNS Drugs. 2009;23(5):419-25
references.pmid: 19453202
references.citation: Psychiatry (Edgmont). 2007 Aug;4(8):39-45
references.pmid: 20532026
references.citation: Am J Drug Alcohol Abuse. 2011 Jul;37(4):235-9
references.pmid: 21517711
references.citation: Clin Ther. 2010 Feb;32(2):252-64
references.pmid: 20206783
references.citation: J Psychiatr Res. 2012 Apr;46(4):484-91
references.pmid: 22277301
references.citation: J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):240-248
references.pmid: 19242289
references.citation: J Child Adolesc Psychopharmacol. 2010 Dec;20(6):503-11
references.pmid: 21186969
references.citation: Clin Drug Investig. 2011;31(6):357-70
references.pmid: 21539403
references.citation: CNS Drugs. 2012 Jul 1;26(7):581-600
references.pmid: 22712698
references.citation: Biol Psychiatry. 2007 Nov 1;62(9):970-6
references.pmid: 17631866
references.citation: Child Adolesc Psychiatry Ment Health. 2009 Jun 09;3(1):17
references.pmid: 19508731
references.citation: J Child Adolesc Psychopharmacol. 2009 Dec;19(6):649-62
references.pmid: 20035583
references.citation: Am J Psychiatry. 2007 Jun;164(6):942-8
references.pmid: 17541055
references.citation: Psychiatry (Edgmont). 2008 Aug;5(8):24-7
references.pmid: 19727272
references.citation: Curr Med Res Opin. 2008 Jan;24(1):33-40
references.pmid: 18021493
references.citation: J Am Acad Child Adolesc Psychiatry. 2011 Apr;50(4):395-405
references.pmid: 21421179
references.citation: J Atten Disord. 2012 Apr;16(3):202-20
references.pmid: 22166471
references.citation: J Atten Disord. 2017 Jan;21(2):149-157
references.pmid: 23657761
references.citation: Postgrad Med. 2010 Sep;122(5):7-17
references.pmid: 20861583
references.citation: Drugs Today (Barc). 2008 May;44(5):319-24
references.pmid: 18548134
references.citation: J Atten Disord. 2011 Aug;15(6):491-8
references.pmid: 20574056
references.citation: Adv Ther. 2013 May;30(5):472-86
references.pmid: 23681505
references.citation: World J Biol Psychiatry. 2013 May;14(4):299-306
references.pmid: 22559155
references.citation: Neuropsychiatr Dis Treat. 2010 May 25;6:273-9
references.pmid: 20520740
references.citation: J Clin Pharmacol. 2008 Mar;48(3):293-302
references.pmid: 18285619
references.citation: Drug Metab Dispos. 2012 Feb;40(2):290-7
references.pmid: 22039171
references.citation: J Psychopharmacol. 2009 Jun;23(4):410-8
references.pmid: 18635707
references.citation: Psychiatry Res. 2013 May 15;207(1-2):127-33
references.pmid: 23062791
references.citation: Behav Brain Funct. 2010 Jun 24;6:34
references.pmid: 20576091
references.citation: J Atten Disord. 2012 Jan;16(1):23-33
references.pmid: 20978273
references.citation: JAMA. 2003 Sep 24;290(12):1600-7
references.pmid: 14506119
references.citation: CNS Spectr. 2008 Jul;13(7):614-20
references.pmid: 18622366
references.citation: Innov Clin Neurosci. 2012 May;9(5-6):22-30
references.pmid: 22808446
references.citation: J Child Adolesc Psychopharmacol. 2012 Apr;22(2):149-56
references.pmid: 22372513
references.citation: J Atten Disord. 2012 Jul;16(5):384-97
references.pmid: 21173426
references.citation: J Clin Psychiatry. 2012 Jul;73(7):977-83
references.pmid: 22780921
references.citation: Curr Med Res Opin. 2005 Feb;21(2):195-206
references.pmid: 15801990
references.citation: J Am Acad Child Adolesc Psychiatry. 2010 Jan;49(1):24-32
references.pmid: 20215923
references.citation: J Clin Psychiatry. 2008 Sep;69(9):1364-73
references.pmid: 19012818
references.citation: CNS Spectr. 2009 Oct;14(10):573-85
references.pmid: 20095369
references.citation: J Clin Psychiatry. 2012 Feb;73(2):192-201
references.pmid: 22313720